- $275.47m
- $246.31m
- €30.06m
- 22
- 17
- 46
- 19
Annual balance sheet for Nanobiotix SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 35.1 | 119 | 83.9 | 41.4 | 75.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.36 | 3.88 | 6.93 | 7.99 | 9.49 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 46.1 | 125 | 93.1 | 52.4 | 87.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.39 | 8.26 | 8.19 | 7.12 | 6.25 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 56.2 | 134 | 102 | 59.8 | 93.9 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 14.3 | 19 | 36.8 | 37.9 | 49.9 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 58.1 | 63.6 | 75 | 86.8 | 95.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -1.91 | 70.5 | 26.8 | -27 | -1.84 |
| Total Liabilities & Shareholders' Equity | 56.2 | 134 | 102 | 59.8 | 93.9 |
| Total Common Shares Outstanding |